100 related articles for article (PubMed ID: 7915508)
1. In vivo expression of P-glycoprotein in a human colon carcinoma xenograft is modulated by therapy with free and monoclonal antibody-conjugated vinca alkaloids.
Hilselberger Kanitz M; Mastro JM; Moore RE; Starling JJ
Anticancer Res; 1994; 14(3A):857-68. PubMed ID: 7915508
[TBL] [Abstract][Full Text] [Related]
2. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.
Starling JJ; Maciak RS; Hinson NA; Hoskins J; Laguzza BC; Gadski RA; Strnad J; Rittmann-Grauer L; DeHerdt SV; Bumol TF
Cancer Res; 1990 Dec; 50(23):7634-40. PubMed ID: 1979247
[TBL] [Abstract][Full Text] [Related]
3. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft.
Rittmann-Grauer LS; Yong MA; Sanders V; Mackensen DG
Cancer Res; 1992 Apr; 52(7):1810-6. PubMed ID: 1348013
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes.
Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA
Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Berlion M; Arvelo F; Leonce S; Bourgeois Y; Rigaudy P; Bizzari JP; Poupon MF
In Vivo; 1993; 7(5):399-405. PubMed ID: 7906553
[TBL] [Abstract][Full Text] [Related]
6. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
Meyer DL; Jungheim LN; Law KL; Mikolajczyk SD; Shepherd TA; Mackensen DG; Briggs SL; Starling JJ
Cancer Res; 1993 Sep; 53(17):3956-63. PubMed ID: 8358723
[TBL] [Abstract][Full Text] [Related]
7. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
Leveille-Webster CR; Arias IA
Clin Cancer Res; 1996 Apr; 2(4):695-706. PubMed ID: 9816220
[TBL] [Abstract][Full Text] [Related]
8. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of P-glycoprotein in human lung carcinoma xenografts after fractionated irradiation in vivo.
Mattern J; Efferth T; Volm M
Radiat Res; 1991 Sep; 127(3):335-8. PubMed ID: 1679564
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of L/1C2-4-desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts.
Johnson DA; Baker AL; Laguzza BC; Fix DV; Gutowski MC
Cancer Res; 1990 Mar; 50(6):1790-4. PubMed ID: 2306731
[TBL] [Abstract][Full Text] [Related]
12. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
13. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D.
Johnson DA; Laguzza BC
Cancer Res; 1987 Jun; 47(12):3118-22. PubMed ID: 3495327
[TBL] [Abstract][Full Text] [Related]
14. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
16. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi.
Xiao H; Wu Z; Shen H; Luo AL; Yang YF; Li XB; Zhu DY
Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):342-8. PubMed ID: 18834355
[TBL] [Abstract][Full Text] [Related]
17. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
Pollack VA; Alvarez E; Tse KF; Torgov MY; Xie S; Shenoy SG; MacDougall JR; Arrol S; Zhong H; Gerwien RW; Hahne WF; Senter PD; Jeffers ME; Lichenstein HS; LaRochelle WJ
Cancer Chemother Pharmacol; 2007 Aug; 60(3):423-35. PubMed ID: 17541593
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4.
Volm M; Bak M; Efferth T; Lathan B; Mattern J
Anticancer Res; 1988; 8(4):531-5. PubMed ID: 2902821
[TBL] [Abstract][Full Text] [Related]
19. Markers of drug resistance in relapsing colon cancer.
Lazaris AC; Kavantzas NG; Zorzos HS; Tsavaris NV; Davaris PS
J Cancer Res Clin Oncol; 2002 Feb; 128(2):114-8. PubMed ID: 11862483
[TBL] [Abstract][Full Text] [Related]
20. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
